Entering text into the input field will update the search result below

BofAML names Sarepta as top pick

Jun. 21, 2019 1:48 PM ETSarepta Therapeutics, Inc. (SRPT) StockSRPTBy: Brandy Betz, SA News Editor
  • Bank of America Merrill Lynch names Sarepta (SRPT -0.2%) as the top small- to mid-cap pick in biotech for H2 and sees several near-term catalysts for the company.
  • The firm cites upside potential from Sarepta's LGMD gene therapy pipeline, which isn't priced into the current valuation.
  • Analyst Tazeen Ahmad says LGMD2E clinical data is encouraging and notes that the treatment doesn't have competition.
  • Ahmad also calls Sarepta a front-runner in DMD with plans to initiate a pivotal commercial supply study by the end of the year.
  • Pfizer will present data for its dystrophin DMD gene therapy at the end of the month. Ahmad writes that in the worst-case scenario, Pfizer would look competitive with Sarepta, an outcome that wouldn't change the analyst's estimates.
  • SRPT has an Outperform average Sell Side rating.

Recommended For You

More Trending News

About SRPT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SRPT--
Sarepta Therapeutics, Inc.